All right. We're going to go ahead and get started with the meeting. Thank you everyone for coming. My name is David Chomiak. I will be moderating this meeting today. I'm an Investment Banking Analyst here at H.C. Wainwright & Co., working on our ECM team. With me here today is Dr. Zaki Rakib, Chairman and CEO of BioHarvest Sciences. He'll be running through his presentation as well as a little Q&A at the end. I want to give him as much time as possible to run through his presentation. With that said, Rakib, it's all yours. Thank you. Good afternoon, everyone. I am Dr. Zaki Rakib. I'm the guy you see on the picture here to tell you about BioHarvest Sciences. I am the Chief Executive Officer and Founder of the company. I've also invested $18 million of my own money into the company. I am 68 years old, and I feel the same energy I had in 1998 when I did an IPO, a roadshow for a company I also founded back in Silicon Valley. I have the same energy and conviction back then when I said to people that we would become a multibillion-dollar company. I'm standing here in front of you, and for those who are listening on the other side of the Ethernet, that I have the same conviction, same energy, and I'm here to tell you why. What we have done at BioHarvest Sciences as a biotech company, you'll be very hard-pressed to find any company in the biotech sphere with this kind of revenue and having a very modest valuation as we speak now. Company did $35 million in revenue last year, and, as I said, we're a biotech company, and I'm here to tell you why you should be investing in the company. First and foremost, I have a very good team. It's a team of veterans from the biotech industry, math, data science, consumer goods, manufacturing, finance, and chemist. I have a very capable team that has been with the company since its inception, most of them, working to build a very unique platform that can leverage plans and produce molecules that are life-changing. The operations of the company is based in Israel, R&D, and manufacturing. We've started trading on NASDAQ a couple of years ago. The company, as I said, generated $35 million in revenue in 2025. On one particular product that was the validation of our platform technology, we have cumulatively sold over $100 million. Our focus is to provide molecules that are plant-based or derived from plants in a consistent and economic way, and we cover four different industries: nutraceutical, pharmaceutical, cosmeceutical, and nutrition. Our goal is, as a CDMO, to develop and manufacture these molecules for those industries. What's common about those industries is they're all looking for nature-based products. Basically, they want the products to be efficacious, they want them to be economic, they want to be consistently produced. Unfortunately, nature is not an industrial supply chain when it comes to biology, when it comes to molecules. Two bananas growing adjacent to each other will produce a different composition inside the cells. The key is how can we leverage all the wealth that exists in nature to remind people about 100 years ago, all medications, all drugs came from plants. Until chemical synthesis came up, everything was extracted from plants. While we are going back to the future, we want to get those great molecules and produce them in aseptic conditions and consistently in bioreactors. To be able to do that, we started with the fundamental science of programmable biology, whereby applying AI models and data science, we can program the conditions under which we expose the cells of the plant to make it produce the molecules at the concentration level we desire. It is not GMO. This is not genetic modification. It is just stressing, literally, the plant cells and force them to produce the molecules which otherwise they produce naturally, but it takes them way longer. I will give you a couple of examples later, some of which we just announced a major supply agreement of $20 million-$30 million over the next couple of years, in the fragrance space. By applying programmable plant biology, we create precision botanics. Why precision? Because we can consistently produce those compositions at the concentration that is desired. We do that initially in small vessels like Erlenmeyers or petri dish, and then we grow them in large-scale bioreactors. One can say that we are the company that industrialized cell culture. The fundamental science behind the programmable biology is the science called cell culture, which has been in existence for maybe over 100 years. But we industrialize it because we are the first company that has taken it to a stage where we can grow things in thousands of liters bioreactors. I am not talking fermentation. This is cell culture technology. The business model is develop, manufacture, collect revenue, and royalties on the unique molecules we produce because no one else can do what we do. We are unique in that space. The process very quickly, which we call Botanical Synthesis, it starts by taking a piece of the plant where the cells of interest are in existence. Then we take those cells, and as I said earlier, we stress them, we create the conditions for them to express the molecules we are interested in, and we create a cell bank. That cell bank we keep forever. That is the over $100 million of a sale of a product we call VINIA that we commercialized based on red grape cells. Same one single grape that was taken 15 years ago or more. Just one grape. I want to stress that. We never go back. We are not doing any agriculture. We took one grape. We took from which the cells, and from that point on, we created the cell bank that we can perpetually use, and that is what you have on the bottom of the screen, where the cells that we plant into the bioreactors get propagated from small scale to mid-scale to large scale bioreactors. In a cycle of three weeks, we basically get mud that we dry and we get the powder, which contains the cells that contain the molecules of interest. Now, what can you do with the powder? You can either sell it as it is like we do, encapsulate it, and we sell it as a dietary supplement. It can go into foods, like the deals we are doing with Tate & Lyle for the sweeteners. It can go as an ingredient for producing fragrances and incense, like the program that we announced throughout last year and the supply agreement that I mentioned earlier that we announced on August 11. Or you can put them in other formats like a chew's. Something that we announced today with VINIA in a chew format, which would be more adequate for younger people and various demographics. Benefits, as I mentioned earlier, are the scalability, lower cost, higher bioavailability with less danger when you look at natural products, less of off-target risks, as well as much higher bioavailability. The consistency is paramount, and on top of everything, as we provide this technology for our customers, everything we do is patentable, meaning the composition is unique and patentable. You are not going to patent a banana, but you can patent the special composition that came from a banana that can be only produced using the process, the Botanical Synthesis process, which is a proprietary process that is protected by patents. Very important, and that is something that we have been doing the last few years, and I mentioned earlier in the programmable biology, we use AI. We use AI to provide us with using machine learning and improving the efficiency and reducing the number of experiments we need to conduct in order to optimize the composition that we need to have. It also provides us with capability to monitor the development itself, to try to reduce, again, the number of tries, and during the manufacturing process to reduce the contamination possibilities. After all, we are a biology factory. In the future, as we are building a library of plant-based molecules, the ability of AI to predict which plant, which molecule would address a certain indication or actually generate ideas down the road. What we have currently in the pipeline, some of which is assets that we have 100% ownership, and some of it are products that we develop for other companies. The first one, the red grape cells, which is the one that we have commercialized as a proof of concept, as a validation for the technology for which we have done a revenue of $33 million last year. Just to give you an example, one molecule, in particular molecule, is called piceid resveratrol, we magnify by a factor of 100. Same thing we do with the olive. We magnify the robustoside by 15x, and in the case of pomegranate. Those three products, we own 100% of them. The others are partial ownership or no ownership. For Tate & Lyle, we have two protein sweeteners that we are developing for them. We do not own parts of those molecules. On the saffron, which is the most researched plant, we have 25% ownership. On the fragrance molecule that we have not announced yet what it is, for purpose of keeping it confidential, at the request of the sponsor of the program based in the United Arab Emirates. That particular fragrance molecule has a market of $15 billion a year. It is a molecule that gets produced by a tree five years after the process of its growth by being attacked by a fungus, and the tree reacts by creating sesquiterpenes and chromones, if we want to get a little technical. Those are, when they are heated, they create the scent or the fragrance itself. The application for the technology, as I said earlier, nutrition, the case Tate & Lyle, fragrance, like the one I mentioned, nutraceuticals. Saffron is also good for nutraceutical as well as it is for food, so we can take it the culinary way or otherwise into the dietary supplement space. VINIA is the product that we commercialized on the basis of the red grape cells. We conducted clinical trials that proved that VINIA is a natural vasodilator. It dilates the blood vessels and hence it improves the blood flow. The company today operates as two divisions. One does the sales direct to the consumer, which is an asset that we want to continue to invest in, and achieve for next year, higher revenue, higher scale, and profitability. Same is happening on the CDMO. With the CDMO, we did $2 million in 2025. We debuted it in 2025. We needed to go through the validation of the technology with VINIA, so we did $2 million. This year, we guided for $4 million - $5 million. That is before even we started manufacturing, like what we start doing in 2027, for the fragrance, and the contract we have is for 20 tons in 2027 and 2028, and the value of this contract is $20 million - $30 million. I mentioned earlier, this is just an illustration of the sesquiterpenes and the chromones for the fragrance. It is a very exciting project. It is also for our planet. You do not need to cut trees because those trees, once you take the bark, you need to basically, you cut them. So our process does not touch any tree. As I said, we only take a sample initially, and then we grow the cells, and we grow the molecules that are providing for the scent. So many application, the fragrance space. Why fragrances? Because there is higher margins. Lower volume, higher margins. We have a factory of 20 tons a year, mostly and predominantly for VINIA. Next year, by the end of next year, we would have built the second factory, also in Israel, for 75 tons to not only produce the growth in VINIA, but also to support the other products like the fragrance, like saffron, or like the other protein sweeteners for Tate & Lyle. The business model. Development revenue, we usually charge $3 million for a development program from scratch, over 18- 24 months. Those are the revenues that we have generated in 2025 and 2026. All of the revenue on the CDMO side are going to be from development. In 2027, we are going to see a mix of development, manufacturing revenue, as well as royalties that stems from the partial ownership or royalties that we charge the customer as a percentage of sales. As I said earlier, the factory that we have today is about 20 tons a year. We are building the 75 tons a year. What is interesting about our technology is that it is actually a very efficient CapEx use. $5 million is what we spent on the first factory. $5 million generates, in consumer good, end price, $50 million a year of revenue. So you can look at the efficiency of the CapEx. Just a snapshot on the financials. The D2C revenue, the VINIA revenue last year was $32.6 million. We guided this year for $33 million-$35 million. The CDMO revenue here as presented includes, if you were to split the two companies, the two divisions, that includes the revenue that would come from in the CDMO from coming from the sale of the VINIA powder into the D2C business. Otherwise, if you subtract it would be about $2 million last year and $4 million-$5 million for this year. Consolidated revenue for 2025 was $34.5 million, for this year it will be $37 million-$40 million. As I said, we are at this inflection point where you have the compounded effect of the revenue that would come in the CDMO from development of more products, more advanced stages that we reach within the development, and then you start compounding for the manufacturing revenue, and on top of it you have the royalties. As I said in the beginning of the presentation, I am here to tell you what I did in 1998 when I IPO'd my first company in the telecom space. I said that this is going to be a multi-billion dollars company. I wasn't wrong. Two years later, the market cap of that company was $7 billion on NASDAQ. We are on NASDAQ, and I truly believe in the prospect of BioHarvest Sciences. There is no such platform, there is no such high biotech story company that has the wealth and technology and already have revenue, that has this kind of low valuation. So, inviting you to take a look at the company. I am available to answer questions and, of course, our partners from LifeSci Advisors are also reachable for any questions that you may have, or any email that you wish to send us with further questions. Thank you very much. All right. At this